tiprankstipranks
Nektar initiated with an Overweight at Piper Sandler
The Fly

Nektar initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Nektar (NKTR) with an Overweight rating and $7 price target The analyst believes Nektar’s lead asset rezpegaldesleukin has a differentiated IL-2Ralpha mechanaism of action that selectively stimulates tregs. The firm has a high probability of success for rezpegaldesleukin, saying the Phase 1b atopic dermatitis trial demonstrated robust efficacy and safety and validated the utility of targeted treg stimulation.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App